CTLA4 and neoplasm: RON is expressed on myeloid cells and recent studies have shown that the anti-tumor activity of anti-CTLA4 antibodies is enhanced in RON kinase domain knockout mice, suggesting that the inhibition of RON may enhance the activity of anti-CTLA4 treatment in enhancing host anti-tumor immunity3.